Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis

This trial is testing a new drug called sotevtamab combined with a standard chemotherapy regimen called FOLFOX to treat colorectal cancer that has spread to the liver. The goal is to shrink the tumors before surgery to remove them. **You may be eligible if...** - You are 18 or older with stage IV colon or rectal cancer that has spread mainly to the liver - Your liver tumors are considered removable by surgery - You have not had chemotherapy for metastatic disease - You are in reasonably good physical condition (able to carry out normal activities) - You have adequate liver, kidney, and immune function **You may NOT be eligible if...** - Your tumor has a specific genetic defect called MMR-deficiency - You have hereditary colorectal cancer syndromes (like Lynch syndrome or familial polyposis) - You have an active HIV, Hepatitis B, or Hepatitis C infection - You are pregnant or breastfeeding - You have pre-existing nerve damage in your hands or feet - You are currently taking high-dose immune-suppressing medications Talk to your doctor to see if this trial is right for you.